Mamatha Pasnoor, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Advisor
    Ineligible company:
    Argenx BVBA Pharmaceuticals
    Topic:
    Myasthenia gravis
    Date added:
    06/07/2026
    Date updated:
    06/07/2026
    Relationship end date:
    03/31/2026
  • Attribution:
    Self
    Type of financial relationship:
    Advisor
    Ineligible company:
    VOR pharmaceuticals
    Topic:
    Myasthenia gravis
    Date added:
    06/07/2026
    Date updated:
    06/07/2026
    Relationship end date:
    04/11/2026
  • Attribution:
    Self
    Type of financial relationship:
    Advisor
    Ineligible company:
    regeneron
    Topic:
    Myasthenia gravis
    Date added:
    06/07/2026
    Date updated:
    06/07/2026
    Relationship end date:
    05/30/2026
  • Attribution:
    Self
    Type of financial relationship:
    Speaker
    Ineligible company:
    Academic CME
    Topic:
    CIDP
    Date added:
    06/07/2026
    Date updated:
    06/07/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Amgen
    Topic:
    Myasthenia Gravis
    Date added:
    06/07/2026
    Date updated:
    06/07/2026
    Relationship end date:
    04/09/2026
  • Attribution:
    Self
    Type of financial relationship:
    Speaker
    Ineligible company:
    Medlive
    Topic:
    Myasthenia gravis
    Date added:
    06/07/2026
    Date updated:
    06/07/2026
    Relationship end date:
    03/09/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Takeda
    Topic:
    CIDP
    Date added:
    06/07/2026
    Date updated:
    06/07/2026
    Relationship end date:
    10/31/2025
Return to Advancing Diagnostic Precision and Treatment Selection in MG